Development and preparation of the EIC Accelerator application: First-in-human trial of CAR13(NAP)-T cells in patients with relapsed glioblastoma.
| Reference number | |
| Coordinator | Elicera Therapeutics AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | June 2025 - October 2025 |
| Status | Ongoing |
| Venture | Global cooperation 2025 |
| Call | Planning grant for international proposal 2025 |
Purpose and goal
This planning project will support Elicera Therapeutics in preparing a complete and competitive application to the EIC Accelerator 2025, October cut-off. The application concerns the clinical validation of ELC-401, a novel CAR-T therapy for glioblastoma, based on the company’s proprietary iTANK platform. The goal is to secure blended funding for a first-in-human Phase I clinical trial starting in 2026.
Expected effects and result
The outcome of the planning project will be a fully developed EIC Accelerator application, including all required technical, financial, and business materials. Elicera will engage expert consultants (GAEU Consulting) and clinical partners to ensure that the application meets the high standards expected by the EIC.
Planned approach and implementation
The planning project will initially focus on developing a high-quality EIC Accelerator application, including the full proposal text including a detailed clinical trial synopsis, financial model, and business case, pitch deck presentation and video. Key activities include refining the trial synopsis in collaboration with clinical partners, identifying and addressing regulatory and documentation gaps to support TRL6 readiness, and validating the commercial and IP strategy.